Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advanced Bionics correction

This article was originally published in The Gray Sheet

Executive Summary

Sylmar, Calif.-based company is conducting European clinical trials of its bion miniature neurostimulator for pudendal nerve stimulation for treating urinary incontinence. So far, the device has been implanted in five patients. The firm plans to launch U.S. trials in the near future. Advanced Bionics notes that the UK National Institute of Clinical Excellence's comments on a neurostimulator for sacral implantation referred exclusively to Medtronic's InterStim, and not bion, as reported by "The Gray Sheet." The tech assessment body described the procedure for sacral nerve stimulation as one for which evidence "currently does not appear" adequate ("1The Gray Sheet" May 5, 2003, p. 19)...

You may also be interested in...



NICE Opens Consultation On AAA Stenting, Other UK Interventional Procedures

New abdominal aortic aneurysm endovascular stent grafts may increase the number of patients who undergo the procedure, according to NICE

ECHA Deliberates On Final Microplastic Proposal As Beauty Industry’s Fate Hangs In Balance

A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.

QUOTED. 2 December. Laurent Faracci.

Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.

UsernamePublicRestriction

Register

PS100968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel